Personalized Therapy for Blood Disorders

Dear Colleagues,

Both adults and children can be affected by blood disorders such as anemia, hemophilia, blood clots and cancers. Among the latter, leukemia, lymphoma and myeloma are known to produce abnormal white blood cells, lymphocytes and plasma cells, respectively. Although an increasing number of treatments are being used to fight blood cancers (e.g., chemotherapy, targeted therapy, radiation therapy, bone marrow transplant, immunotherapy and CAR-T cell therapy), disease heterogeneity can hinder the choice of treatment and its efficiency. Therefore, blood cancer patients might require more individualized disease management through the use of personalized medicine approaches.

This Special Issue aims to publish articles describing blood cancer heterogeneity and personalized care strategies for diagnosis, prognosis and treatment response.

Personalized care can provide more accurate prognosis and therapy response predictions than standard procedures. Molecular descriptions by different omics technologies are powerful approaches to individual-based treatments.

I invite the submission of manuscripts describing personalized care based on the use of omics technologies to better describe diagnosis and prognosis as well as reviews on the latest uses of personalized medicine approaches. Debate on the implementation of personalized molecular approaches in the clinical setting and how patients could be integrated in the decision-making process is especially welcome.

Dr. Maria Hernandez-Valladares
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.